[시장보고서]고효능 원료의약품(HPAPI) 시장(2024-2034년)

고효능 원료의약품(HPAPI) 시장(2024-2034년)

Highly Potent Active Pharmaceutical Ingredients (HPAPIs) Market Report 2024-2034

상품코드 : 1503263

리서치사 : Visiongain

발행일 : 2024년 06월

페이지 정보 : 영문 335 Pages

라이선스 & 가격 (부가세 별도)

￡ 4,350

￦ 8,149,000

Unprintable PDF (Single User) - 1 Year License

보고서 PDF를 1명만 이용할 수 있는 라이선스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF(이용기간은 구매일로부터 1년)로 제공되며, 인증된 PC 1대에서만 열람 가능합니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

￡ 5,150

￦ 9,648,000

PDF (Team License - Up to 6 Users) - 1 Year License

보고서 PDF를 동일 사업장(소재지) 내의 6명까지 이용할 수 있는 라이선스입니다. PDF 내 텍스트 등의 Copy&Paste는 불가능합니다. DRM(디지털 저작권 관리 시스템) 장착 PDF(이용기간은 구매일로부터 1년)이며, 인증된 PC상에서 열람 가능합니다. 인쇄는 1명당 1회만 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

￡ 6,050

￦ 11,334,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 1명당 1회만 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

￡ 7,645

￦ 14,322,000

PDF (Enterprise License - Includes Free Datasets)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 고효능 원료의약품(HPAPI) 시장 규모는 2034년까지 CAGR 9.6%로 성장할 것으로 예측되고 있습니다.

만성질환의 증가가 시장 성장을 촉진 :

암, 심혈관질환, 당뇨병, 자가면역질환 등의 만성질환은 장기적인 치료와 지속적인 관리가 필요합니다. 이러한 질병을 관리하기 위한 효과적인 약물에 대한 수요가 높으며, HPAPI는 효능과 특정 질병 경로를 표적으로 삼는 능력으로 인해 이러한 약물에 필수적이며, HPAPI는 표적 치료제 및 생물학적 제제와 같은 첨단 치료제를 만드는 데 중요한 역할을 하고 있습니다. 예를 들어 종양 분야에서 HPAPI는 건강한 조직에 해를 끼치지 않으면서 암세포를 파괴하는 데 초점을 맞춘 화학요법 및 표적치료제에 활용되고 있습니다. 이러한 표적화된 접근법은 만성질환을 효과적으로 관리하고 치료하는 데 필수적입니다. 제약사들은 만성질환을 효과적으로 관리할 수 있는 신약을 개발하기 위해 R&D에 지속적으로 자원을 투입하고 있습니다. 저용량으로 높은 효능을 발휘하는 고약리활성원료(HPAPI)는 이러한 제제에 필수적인 요소입니다. 이 접근법은 환자의 예후를 개선할 뿐만 아니라 부작용을 최소화하고 치료를 보다 쉽게 관리할 수 있도록 돕습니다. HPAPI는 평생 약물 치료가 필요한 만성질환 환자들에게 치료 효과를 연장하고, 투여 횟수를 줄이며, 치료 요법에 대한 순응도를 향상시키는 약물의 개발을 촉진합니다.

비감염성 질환(NCD)에 의해 매년 4,100만 명이 사망하고 있으며, 이것은 세계 전체 사망자 수의 74%에 상당합니다. 매년 1,700만 명이 70세까지 NCD로 사망하고 있으며, 이 중 86%가 중저소득국에서 발생하고 있습니다.

높은 제조 비용이 산업 성장의 방해가 될 가능성이 높다. :

HPAPI의 제조에는 안전성과 규제 준수를 확보하기 위해 특수한 시설, 설비, 격납 시스템에 거액의 자본 투자가 필요합니다. 이러한 높은 초기 비용과 지속적인 운영 비용은 중소기업 시장 진입을 막거나 기존 기업의 생산 능력 확장을 제한할 수 있으며, HPAPI 제조에는 높은 효능과 순도를 유지하면서 안전성을 보장하기 위한 복잡하고 정밀한 공정이 포함됩니다. 이러한 공정은 첨단 기술, 숙련된 인력, 엄격한 품질관리 조치가 필요한 경우가 많으며, 이 모든 것이 제조 비용 상승의 원인이 되고 있습니다.

세계의 고효능 원료의약품(HPAPI) 시장을 조사했으며, 시장 개요, 시장 성장에 대한 영향요인 및 시장 기회의 분석, 시장 규모의 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

경쟁 환경
전략적 전망
AbbVie Inc.
Bayer AG
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Company
Cambrex Corporation
Catalent, Inc
Cipla Inc.
Dr. Reddy's Laboratories
Eli Lilly and Company
F. Hoffmann-La Roche AG
Merck &Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

제16장 결론·제안

Visiongain으로부터의 결론
시장 참여 기업에 대한 제안

KSA

영문 목차

영문목차

The global Highly Potent Active Pharmaceutical Ingredients Market is Projected to Grow at a CAGR of 9.6% by 2034

The Highly Potent Active Pharmaceutical Ingredients (HPAPIs) Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Incidence of Chronic Diseases Driving Market Growth

Chronic illnesses, including cancer, cardiovascular conditions, diabetes, and autoimmune disorders, necessitate prolonged treatment and ongoing management. The demand for effective medications to manage these conditions is high, and HPAPIs are often integral to these medications due to their potency and ability to target specific disease pathways. HPAPIs play a vital role in creating advanced treatments, such as targeted therapies and biologics. In the field of oncology, for example, HPAPIs are utilized in chemotherapeutic drugs and targeted treatments that focus on destroying cancer cells while reducing harm to healthy tissue. This targeted approach is essential for effectively managing and treating chronic diseases. Pharmaceutical companies are consistently pouring resources into research and development to develop new medications that can effectively manage chronic diseases. High Potency Active Pharmaceutical Ingredients (HPAPIs) are vital in these formulations, providing high efficacy at lower doses. This approach not only enhances patient outcomes but also minimizes side effects, making treatments more manageable. For patients with chronic illnesses who need lifelong medication, HPAPIs facilitate the creation of drugs that offer prolonged therapeutic effects, decrease dosing frequency, and improve adherence to treatment regimens.

Non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Each year, 17 million people die from a NCD before age 70; 86% of these premature deaths occur in low- and middle-income countries.

High Manufacturing Costs Likely to Hamper Industry Growth

Manufacturing HPAPIs requires substantial capital investment in specialized facilities, equipment, and containment systems to ensure safety and regulatory compliance. These high initial and ongoing operational costs can deter smaller companies from entering the market or limit the ability of existing companies to expand their production capacities. The production of HPAPIs involves complex and precise processes to maintain high potency and purity while ensuring safety. These processes often require advanced technology, skilled personnel, and stringent quality control measures, all of which contribute to higher manufacturing costs.

What Questions Should You Ask before Buying a Market Research Report?

How is the highly potent active pharmaceutical ingredients market evolving?

What is driving and restraining the Highly potent active pharmaceutical ingredients Market?

How will each highly potent active pharmaceutical ingredients submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each highly potent active pharmaceutical ingredients submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading highly potent active pharmaceutical ingredients markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the highly potent active pharmaceutical ingredients projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of highly potent active pharmaceutical ingredients projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the highly potent active pharmaceutical ingredients market?

Where is the highly potent active pharmaceutical ingredients market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Highly Potent Active Pharmaceutical Ingredients Market today, and over the next 10 years:

Our 335-page report provides 124 tables and 220 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising highly potent active pharmaceutical ingredients prices and recent developments.

Segments Covered in the Report

Product

Synthetic

Biotech

Manufacturer Type

In-house

Outsource

Drug Type

Innovative

Generic

Dosage Form

Solids

Liquids

Injectable

Others

Application

Oncology

Hormonal Imbalance

Glaucoma

Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 27 leading national markets:

North America

U.S.

Canada

Europe

Germany

France

Spain

Italy

Poland

Belgium

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Colombia

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles for some of the leading companies in the Highly Potent Active Pharmaceutical Ingredients Market 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

Bayer AG

Boehringer Ingelheim International GmbH

Bristol Myers Squibb Company

Cambrex Corporation

Catalent, Inc

Cipla Inc.

Dr Reddy's Laboratories

Eli Lilly and Company

F. Hoffmann-La Roche AG

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Sanofi

Teva Pharmaceutical Industries Ltd.

Overall world revenue for Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034 in terms of value the market will surpass US$29,600 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034 report help you?

In summary, our 330+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034, with forecasts for product, manufacturer, drug type, dosage form, and application each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 27 key national markets - See forecasts for the Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Highly Potent Active Pharmaceutical Ingredients Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Highly Potent Active Pharmaceutical Ingredients Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
  - 1.7.3.1 Primary Research
  - 1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
- 3.3.1 Market Driving Factors
  - 3.3.1.1 Increasing Incidence of Chronic Diseases
  - 3.3.1.2 Advancements in Oncology Research
  - 3.3.1.3 Growing Emphasis on Personalized Medicine
- 3.3.2 Market Restraining Factors
  - 3.3.2.1 Stringent Regulatory Requirements
  - 3.3.2.2 High Developmental Cost for HPAPIs
  - 3.3.2.3 Susceptibility to Supply Chain Disruptions
- 3.3.3 Market Opportunities
  - 3.3.3.1 Growing Investments in Infrastructure and Capacity Expansion
  - 3.3.3.2 Lucrative Growth Opportunities in Emerging Markets
  - 3.3.3.3 Increasing Collaborations and Partnerships Between Industry Participants
3.4 Emerging Markets and Megatrends
3.5 Porter's Five Forces Analysis
- 3.5.1 Bargaining Power of Suppliers
- 3.5.2 Bargaining Power of Buyers
- 3.5.3 Competitive Rivalry
- 3.5.4 Threat of Substitutes
- 3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Product

4.1 Key Findings
4.2 Product Segment: Market Attractiveness Index
4.3 Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Product
4.4 Synthetic
- 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Biotech
- 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Manufacturer Type

5.1 Key Findings
5.2 Product Segment: Market Attractiveness Index
5.3 Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Manufacturer Type
5.4 In-house
- 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Outsource
- 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.2 Market Share by Region, 2024 & 2034 (%)

6 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Drug Type

6.1 Key Findings
6.2 Drug Type Segment: Market Attractiveness Index
6.3 Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Drug Type
6.4 Innovative
- 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Generic
- 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Dosage Form

7.1 Key Findings
7.2 Dosage Form Segment: Market Attractiveness Index
7.3 Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Dosage Form
7.4 Solids
- 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Liquids
- 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Injectable
- 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Others
- 7.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Application

8.1 Key Findings
8.2 Application Segment: Market Attractiveness Index
8.3 Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Application
8.4 Oncology
- 8.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 8.4.2 Market Share by Region, 2024 & 2034 (%)
8.5 Hormonal Imbalance
- 8.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Glaucoma
- 8.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 8.6.2 Market Share by Region, 2024 & 2034 (%)
8.7 Others
- 8.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 8.7.2 Market Share by Region, 2024 & 2034 (%)

9 Highly Potent Active Pharmaceutical Ingredients Market Analysis by Region

9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America Highly Potent Active Pharmaceutical Ingredients Market Analysis

10.1 Key Findings
10.2 North America Highly Potent Active Pharmaceutical Ingredients Market Attractiveness Index
10.3 North America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Country
10.4 North America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Product
10.5 North America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Manufacturer Type
10.6 North America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Drug Type
10.7 North America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Dosage Form
10.8 North America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Application
10.9 U.S. Highly Potent Active Pharmaceutical Ingredients Market Analysis
10.10 Canada Highly Potent Active Pharmaceutical Ingredients Market Analysis

11 Europe Highly Potent Active Pharmaceutical Ingredients Market Analysis

11.1 Key Findings
11.2 Europe Highly Potent Active Pharmaceutical Ingredients Market Attractiveness Index
11.3 Europe Highly Potent Active Pharmaceutical Ingredients Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Europe Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Country
11.5 Europe Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Product
11.6 Europe Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Manufacturer Type
11.7 Europe Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Drug Type
11.8 Europe Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Dosage Form
11.9 Europe Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Application
11.10 Germany Highly Potent Active Pharmaceutical Ingredients Market Analysis
11.11 UK Highly Potent Active Pharmaceutical Ingredients Market Analysis
11.12 France Highly Potent Active Pharmaceutical Ingredients Market Analysis
11.13 Spain Highly Potent Active Pharmaceutical Ingredients Market Analysis
11.14 Italy Highly Potent Active Pharmaceutical Ingredients Market Analysis
11.15 Poland Highly Potent Active Pharmaceutical Ingredients Market Analysis
11.16 Belgium Highly Potent Active Pharmaceutical Ingredients Market Analysis
11.17 Russia Highly Potent Active Pharmaceutical Ingredients Market Analysis
11.18 Rest of Europe Highly Potent Active Pharmaceutical Ingredients Market Analysis

12 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Analysis

12.1 Key Findings
12.2 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Attractiveness Index
12.3 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Country
12.5 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Product
12.6 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Manufacturer Type
12.7 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Drug Type
12.8 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Dosage Form
12.9 Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Application
12.10 Japan Highly Potent Active Pharmaceutical Ingredients Market Analysis
12.11 China Highly Potent Active Pharmaceutical Ingredients Market Analysis
12.12 India Highly Potent Active Pharmaceutical Ingredients Market Analysis
12.13 Australia Highly Potent Active Pharmaceutical Ingredients Market Analysis
12.14 South Korea Highly Potent Active Pharmaceutical Ingredients Market Analysis
12.15 Singapore Highly Potent Active Pharmaceutical Ingredients Market Analysis
12.16 Taiwan Highly Potent Active Pharmaceutical Ingredients Market Analysis
12.17 Rest of Asia Pacific Highly Potent Active Pharmaceutical Ingredients Market Analysis

13 Latin America Highly Potent Active Pharmaceutical Ingredients Market Analysis

13.1 Key Findings
13.2 Latin America Highly Potent Active Pharmaceutical Ingredients Market Attractiveness Index
13.3 Latin America Highly Potent Active Pharmaceutical Ingredients Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 Latin America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Country
13.5 Latin America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Product
13.6 Latin America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Manufacturer Type
13.7 Latin America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Drug Type
13.8 Latin America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Dosage Form
13.9 Latin America Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Application
13.10 Brazil Highly Potent Active Pharmaceutical Ingredients Market Analysis
13.11 Mexico Highly Potent Active Pharmaceutical Ingredients Market Analysis
13.12 Argentina Highly Potent Active Pharmaceutical Ingredients Market Analysis
13.13 Colombia Highly Potent Active Pharmaceutical Ingredients Market Analysis
13.14 Rest of Latin America Highly Potent Active Pharmaceutical Ingredients Market Analysis

14 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Analysis

14.1 Key Findings
14.2 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Attractiveness Index
14.3 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market by Country, 2024, 2029 & 2034 (US$ Million)
14.4 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Country
14.5 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Product
14.6 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Manufacturer Type
14.7 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Drug Type
14.8 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Dosage Form
14.9 Middle East and Africa Highly Potent Active Pharmaceutical Ingredients Market Size Estimation and Forecast by Application
14.10 GCC Highly Potent Active Pharmaceutical Ingredients Market Analysis
14.11 South Africa Highly Potent Active Pharmaceutical Ingredients Market Analysis
14.12 Rest of MEA Highly Potent Active Pharmaceutical Ingredients Market Analysis

15 Company Profiles

15.1 Competitive Landscape, 2023
15.2 Strategic Outlook
15.3 AbbVie Inc.
- 15.3.1 Company Snapshot
- 15.3.2 Company Overview
- 15.3.3 Financial Analysis
  - 15.3.3.1 Net Revenue, 2017-2023
  - 15.3.3.2 R&D, 2017-2023
  - 15.3.3.3 Regional Market Shares, 2023
  - 15.3.3.4 Business Segment Market Shares, 2023
- 15.3.4 Product Benchmarking
- 15.3.5 Strategic Outlook
- 15.3.6 SWOT Analysis
15.4 Bayer AG
- 15.4.1 Company Snapshot
- 15.4.2 Company Overview
- 15.4.3 Financial Analysis
  - 15.4.3.1 Net Revenue, 2017-2023
  - 15.4.3.2 R&D, 2017-2023
  - 15.4.3.3 Regional Market Shares, 2023
- 15.4.4 Product Benchmarking
- 15.4.5 Strategic Outlook
- 15.4.6 SWOT Analysis
15.5 Boehringer Ingelheim International GmbH
- 15.5.1 Company Snapshot
- 15.5.2 Company Overview
- 15.5.3 Financial Analysis
  - 15.5.3.1 Net Revenue, 2017-2023
  - 15.5.3.2 R&D, 2017-2023
  - 15.5.3.3 Regional Market Shares, 2023
  - 15.5.3.4 Business Segment Market Shares, 2023
- 15.5.4 Product Benchmarking
- 15.5.5 Strategic Outlook
- 15.5.6 SWOT Analysis
15.6 Bristol Myers Squibb Company
- 15.6.1 Company Snapshot
- 15.6.2 Company Overview
- 15.6.3 Financial Analysis
  - 15.6.3.1 Net Revenue, 2017-2023
  - 15.6.3.2 R&D, 2017-2023
  - 15.6.3.3 Regional Market Shares, 2023
  - 15.6.3.4 Business Segment Market Shares, 2023
- 15.6.4 Product Benchmarking
- 15.6.5 Strategic Outlook
- 15.6.6 SWOT Analysis
15.7 Cambrex Corporation
- 15.7.1 Company Snapshot
- 15.7.2 Company Overview
- 15.7.3 Product Benchmarking
- 15.7.4 Strategic Outlook
- 15.7.5 SWOT Analysis
15.8 Catalent, Inc
- 15.8.1 Company Snapshot
- 15.8.2 Company Overview
- 15.8.3 Financial Analysis
  - 15.8.3.1 Net Revenue, 2017-2023
  - 15.8.3.2 Regional Market Shares, 2023
  - 15.8.3.3 Business Segment Market Shares, 2023
- 15.8.4 Product Benchmarking
- 15.8.5 Strategic Outlook
- 15.8.6 SWOT Analysis
15.9 Cipla Inc.
- 15.9.1 Company Snapshot
- 15.9.2 Company Overview
- 15.9.3 Financial Analysis
  - 15.9.3.1 Net Revenue, 2017-2023
  - 15.9.3.2 R&D, 2017-2023
  - 15.9.3.3 Regional Market Shares, 2023
  - 15.9.3.4 Business Segment Market Shares, 2023
- 15.9.4 Product Benchmarking
- 15.9.5 Strategic Outlook
- 15.9.6 SWOT Analysis
15.10 Dr. Reddy's Laboratories
- 15.10.1 Company Snapshot
- 15.10.2 Company Overview
- 15.10.3 Financial Analysis
  - 15.10.3.1 Net Revenue, 2017-2023
  - 15.10.3.2 R&D, 2017-2023
  - 15.10.3.3 Regional Market Shares, 2023
  - 15.10.3.4 Business Segment Market Shares, 2023
- 15.10.4 Product Benchmarking
- 15.10.5 Strategic Outlook
- 15.10.6 SWOT Analysis
15.11 Eli Lilly and Company
- 15.11.1 Company Snapshot
- 15.11.2 Company Overview
- 15.11.3 Financial Analysis
  - 15.11.3.1 Net Revenue, 2017-2023
  - 15.11.3.2 R&D, 2017-2023
  - 15.11.3.3 Regional Market Shares, 2023
  - 15.11.3.4 Business Segment Market Shares, 2023
- 15.11.4 Product Benchmarking
- 15.11.5 Strategic Outlook
- 15.11.6 SWOT Analysis
15.12 F. Hoffmann-La Roche AG
- 15.12.1 Company Snapshot
- 15.12.2 Company Overview
- 15.12.3 Financial Analysis
  - 15.12.3.1 Net Revenue, 2017-2023
  - 15.12.3.2 R&D, 2017-2023
  - 15.12.3.3 Business Segment Market Shares, 2023
- 15.12.4 Product Benchmarking
- 15.12.5 Strategic Outlook
- 15.12.6 SWOT Analysis
15.13 Merck & Co., Inc.
- 15.13.1 Company Snapshot
- 15.13.2 Company Overview
- 15.13.3 Financial Analysis
  - 15.13.3.1 Net Revenue, 2017-2023
  - 15.13.3.2 R&D, 2017-2023
  - 15.13.3.3 Regional Market Shares, 2023
  - 15.13.3.4 Business Segment Market Shares, 2023
- 15.13.4 Product Benchmarking
- 15.13.5 Strategic Outlook
- 15.13.6 SWOT Analysis
15.14 Novartis AG
- 15.14.1 Company Snapshot
- 15.14.2 Company Overview
- 15.14.3 Financial Analysis
  - 15.14.3.1 Net Revenue, 2017-2023
  - 15.14.3.2 R&D, 2017-2023
  - 15.14.3.3 Regional Market Shares, 2023
  - 15.14.3.4 Business Segment Market Shares, 2023
- 15.14.4 Product Benchmarking
- 15.14.5 Strategic Outlook
- 15.14.6 SWOT Analysis
15.15 Pfizer Inc.
- 15.15.1 Company Snapshot
- 15.15.2 Company Overview
- 15.15.3 Financial Analysis
  - 15.15.3.1 Net Revenue, 2017-2023
  - 15.15.3.2 R&D, 2017-2023
  - 15.15.3.3 Regional Market Shares, 2023
  - 15.15.3.4 Business Segment Market Shares, 2023
- 15.15.4 Product Benchmarking
- 15.15.5 Strategic Outlook
- 15.15.6 SWOT Analysis
15.16 Sanofi
- 15.16.1 Company Snapshot
- 15.16.2 Company Overview
- 15.16.3 Financial Analysis
  - 15.16.3.1 Net Revenue, 2017-2023
  - 15.16.3.2 R&D, 2017-2023
- 15.16.4 Product Benchmarking
- 15.16.5 Strategic Outlook
- 15.16.6 SWOT Analysis
15.17 Teva Pharmaceutical Industries Ltd.
- 15.17.1 Company Snapshot
- 15.17.2 Company Overview
- 15.17.3 Financial Analysis
  - 15.17.3.1 Net Revenue, 2017-2023
  - 15.17.3.2 R&D, 2017-2023
  - 15.17.3.3 Regional Market Shares, 2023
- 15.17.4 Product Benchmarking
- 15.17.5 Strategic Outlook
- 15.17.6 SWOT Analysis

16 Conclusion and Recommendations

16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

한글목차

목차

제1장 리포트 개요

제2장 주요 요약

제3장 시장 개요

제4장 고효능 원료의약품(HPAPI) 시장 분석 : 제품별

제5장 고효능 원료의약품(HPAPI) 시장 분석 : 제조업체 유형별

제6장 고효능 원료의약품(HPAPI) 시장 분석 : 약제 유형별

제7장 고효능 원료의약품(HPAPI) 시장 분석 : 제형별

제8장 고효능 원료의약품(HPAPI) 시장 분석 : 용도별

제9장 고효능 원료의약품(HPAPI) 시장 분석 : 지역별

제10장 북미의 고효능 원료의약품(HPAPI) 시장 분석

제11장 유럽의 고효능 원료의약품(HPAPI) 시장 분석

제12장 아시아태평양의 고효능 원료의약품(HPAPI) 시장 분석

제13장 라틴아메리카의 고효능 원료의약품(HPAPI) 시장 분석

제14장 중동 및 아프리카의 고효능 원료의약품(HPAPI) 시장 분석

제15장 기업 개요